戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 olving the crystal structure of two FR3 loop-chimeric antibodies.
2   The development of a therapeutic anti-CD99 chimeric antibody, 10D1, with a membrane-proximal bindin
3 , we report the development of a recombinant chimeric antibody (Ab-1) against basigin, an erythrocyte
4          Anti-CD28-PV1-IgG3, a hamster-mouse chimeric antibody against murine CD28, which does not pr
5 ng murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the guinea pig mode
6 plied the analysis to a set of humanized and chimeric antibodies and to human germline sequences.
7 hich makes humanized antibody or human-mouse chimeric antibody available for clinical trials, signifi
8 nsfer of tumor-specific T cells that express chimeric antibody-based receptors (CAR) to mice with pri
9 ntibodies on the viral envelope, including a chimeric antibody binding protein and a SNAP-tag enablin
10                                The resultant chimeric antibodies bound the HIV-1 envelope (Env) trime
11                                          The chimeric antibody (cAb 26-2F) binds to Ang and inhibits
12 orrelation between results obtained with the chimeric antibody calibrators and the positive human pla
13 ecognition of SSEA-4 by a novel monospecific chimeric antibody (ch28/11).
14 e developed a novel tumor-specific anti-EGFR chimeric antibody ch806 labeled with (225)Ac and evaluat
15 d a germ-line heavy-chain/mature light-chain chimeric antibody complexed with HIV-1 gp120.
16                                              Chimeric antibodies composed of heavy and light chains,
17 f-life, we have investigated two families of chimeric antibodies, composed of identical murine heavy
18           AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the tr
19                                The resulting chimeric antibody, designated SGN-30, retained the bindi
20           Compared to unmodified antibodies, chimeric antibodies display lower autoreactivity and pro
21                                          The chimeric antibodies exhibited immunoreactivity and affin
22                         Z2D3 is a monoclonal chimeric antibody fragment that is directed against a pr
23                             To develop human chimeric antibodies, H2L2 Harbor Mice(R), which express
24                       Examination of the IgM chimeric antibodies in the IMx Toxo IgM assay revealed t
25 To investigate this question, we constructed chimeric antibodies in which the human IgG1 constant reg
26 the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose syst
27                 To mimic IgG opsonization, a chimeric antibody-like molecule, containing human IgG1 F
28  develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with
29 70-specific antibody (FR70) or IgG1 or IgG2a chimeric antibodies on days 0, 2, 4, and 6 posttransplan
30 llogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell
31 a high-affinity immunoglobulin G(1) (IgG(1)) chimeric antibody recognizing an N-linked carbohydrate e
32 cells have been most widely used, led by the chimeric antibody rituximab, now used in nearly all type
33 ht chain from VRC01, half of the heavy chain chimeric antibodies showed substantial neutralization po
34 the context of chronic autoimmunity, we used chimeric antibodies specific for DC inhibitory receptor
35                                 We generated chimeric antibodies that combine the vaccine-elicited so
36 d antibody, DMB5F3, we created a recombinant chimeric antibody that bound a panel of MUC1+ cancer cel
37 two neutralizing antibodies and engineered a chimeric antibody that cross-neutralizes several poxviru
38                                 Rituximab, a chimeric antibody that targets CD20(+) B cells, produces
39 ith the loss of immature B cells bearing 2F5 chimeric antibodies to central tolerance mechanisms.
40    The antibody, rituximab, is a mouse/human chimeric antibody to human CD20 antigen.
41                                InflixiMAB, a chimeric antibody to human TNF-alpha, was recently appro
42 eptor (FcRB) to delay saturation of human or chimeric antibodies via differential catabolism of antig
43       No quantifiable immune response to the chimeric antibody was detected.
44                         The plant-expressed, chimeric antibody was purified and biochemically charact
45 factor (bGCSF) results in a stably expressed chimeric antibody, which proliferates mouse NFS-60 cells
46 ha or PDGFR-beta with a specific mouse/human chimeric antibody will modulate flow-induced neointimal
47 t mutations in the human Fc region of bovine chimeric antibodies with ultralong CDRH3s could enhance